Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Cytokine Release Syndrome 1

Interventions

Taxes 2Paclitaxel 2Oxaliplatin 2Magnesium Sulfate 2Carboplatin 2Calcium Gluconate 2haloperidol decanoate 1glutamic acid diethyl ester 1axicabtagene ciloleucel 1Vitamin E 1Vincristine 1Thalidomide 1Surveys and Questionnaires 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Procarbazine 1Peripheral Blood Stem Cell Transplantation 1Pain Management 1Modafinil 1Methotrexate 1Memantine 1Melphalan 1Lorazepam 1Leucovorin 1Lamotrigine 1Ketamine 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurotoxicity Syndromes × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡